Cargando…
Molecular profiles of different PD-L1 expression in patients with esophageal squamous cell carcinoma
BACKGROUND: PD-1/PD-L1 inhibitors are approved treatments for patients with esophageal squamous cell carcinoma (ESCC). The present investigation aspired to explore the interrelation between molecular phenotype and PD-L1 expression in ESCC. METHODS: PD-L1 testing and targeted next-generation sequenci...
Autores principales: | Zhao, Songchen, Hu, Xintong, Zhou, Peiwen, Li, Ang, Chen, Liguo, Wang, Duo, He, Jiaxue, Jiang, Yanfang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515684/ https://www.ncbi.nlm.nih.gov/pubmed/38032149 http://dx.doi.org/10.1080/15384047.2023.2256927 |
Ejemplares similares
-
Characteristics of Genomic Alterations in Pericardial Effusion of Advanced Non-small Cell Lung Cancer
por: He, Jiaxue, et al.
Publicado: (2022) -
Combining Genetic Mutation and Expression Profiles Identifies Novel
Prognostic Biomarkers of Lung Adenocarcinoma
por: Liu, Yun, et al.
Publicado: (2020) -
Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis
por: Guo, Wei, et al.
Publicado: (2017) -
RNF168 is highly expressed in esophageal squamous cell carcinoma and contributes to the malignant behaviors in association with the Wnt/β-catenin signaling pathway
por: Gou, Yunjiu, et al.
Publicado: (2021) -
PD‐L1 and PD‐L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma
por: Okadome, Kazuo, et al.
Publicado: (2021)